Dark Forest Capital Management LP Has $667,000 Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dark Forest Capital Management LP increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 54.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,657 shares of the pharmaceutical company's stock after acquiring an additional 585 shares during the quarter. Dark Forest Capital Management LP's holdings in Vertex Pharmaceuticals were worth $667,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Brown Lisle Cummings Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. Sugar Maple Asset Management LLC purchased a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $35,000. Golden State Wealth Management LLC purchased a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth $37,000. Truvestments Capital LLC lifted its holdings in Vertex Pharmaceuticals by 30.3% during the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after buying an additional 23 shares in the last quarter. Finally, ORG Partners LLC grew its stake in Vertex Pharmaceuticals by 108.2% during the 4th quarter. ORG Partners LLC now owns 102 shares of the pharmaceutical company's stock worth $41,000 after purchasing an additional 53 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX traded up $2.48 during trading on Wednesday, reaching $505.98. The stock had a trading volume of 255,930 shares, compared to its average volume of 1,336,434. The firm has a market capitalization of $130.08 billion, a price-to-earnings ratio of -229.45, a P/E/G ratio of 2.11 and a beta of 0.50. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The stock has a fifty day simple moving average of $490.74 and a two-hundred day simple moving average of $466.65.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. BMO Capital Markets set a $545.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price target on the stock. in a report on Thursday, January 30th. Royal Bank of Canada boosted their target price on shares of Vertex Pharmaceuticals from $408.00 to $420.00 and gave the company a "sector perform" rating in a research note on Tuesday, April 1st. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $535.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, April 22nd. Ten research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $514.91.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 310 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total transaction of $142,547.30. Following the sale, the executive vice president now owns 64,021 shares of the company's stock, valued at $29,438,776.43. This represents a 0.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the sale, the executive vice president now directly owns 26,512 shares of the company's stock, valued at approximately $13,256,000. This represents a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,315 shares of company stock valued at $2,121,012 over the last quarter. Corporate insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.